Wedgewood's Pimobendan Injection Solution is a US-compounded medication for the emergency treatment of canine patients in acute decompensated congestive heart failure (ADHF) due to MMVD or DCM. Available for office stock, it gives your team an IV option for use in emeergency situations.
| Product Details | |
|---|---|
| Strength | 0.75mg/ml |
| Size | 10ml |
| Form | Preservative-free, single-dose vial |
| Storage | Refrigerated |
| BUD | 60 days |
| Ordering | Office Stock* or Prescription |
Wedgewood's compounded pimobendan injection gives your team an option in the moments oral dosing doesn't fit the patient in front of you.
Injectable Pimobendan is an option for moments when oral dosing is not appropriate due to patient status. This compounded medication is not a replacement for oral therapy.
No. It's indicated for the emergency treatment of canine patients in ADHF due to MMVD or DCM, not a substitute for chronic maintenance therapy.
Pimobendan Injection Solution was nominated to the FDA’s list of office stock drugs and is currently under review, per GFI #256. This means that this medication can be sold to practices for office stock in all states except Hawaii, Montana, New York, Oregon, Rhode Island, South Dakota, and Washington D.C. Veterinarians who work in a state that does not allow USP compounded medications for office stock can prescribe this compounded medication in a patient’s name.
The beyond-use date is 60 days from the date of compounding. We are pursuing stability studies to extend the BUD.
The HD label reflects Wedgewood's production facility designation, not the medication's hazard classification. Pimobendan is not classified as hazardous and is not a controlled substance. All handling guidance is included with the shipment of an order.
*Office stock availability subject to state restrictions.